ArticleIn vivo (Athens, Greece)
Simultaneous Investigation of sST2, IL-33, and Caspase-3 Serum Levels in Non-small Cell Lung Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunomodulatory mediators IL-33, soluble ST2, IL-10, IFN-Frontiers in oral health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimNon-small cell lung cancer (NSCLC) is a type of lung cancer with a high mortality rate. Many molecular and biochemical mechanisms are involved in its development, among which the suppression of tumorigenicity-2 protein (ST2) signaling pathway. Soluble ST2 (sST2) competes with transmembrane ST2 (ST2 ligand) for IL-33 binding. Activation of IL-33/ST2 pathway leads to M2 macrophage polarization, which promotes tumor progression. Since Caspase-3 is implicated in the regulation of IL-33 activity, the present study aimed to analyze the serum levels of IL-33, sST2, and caspase-3 in non-small cell lung cancer patients, compare them with control samples, and simultaneously investigate their predictive capacity. MATERIALS AND
methodsIn this study, sST2 protein, IL-33, and caspase-3 levels were investigated using the ELISA method in serum samples collected from 25 patients diagnosed with non-small cell lung cancer and 25 completely healthy volunteer individuals. In the study, receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic power of the biomarkers.
resultsSerum IL-33 levels were found to be significantly elevated in patients compared to the control group (
conclusionNSCLC patients are characterized by increased IL-33 and caspase-3 serum levels. These findings suggest that these markers could serve as valuable diagnostic and prognostic indicators, in addition to being potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.